AstraZeneca Says Its COVID-19 Vaccine Produces Robust Immune Response In Elderly Patients

Days after US regulators gave the AstraZeneca - Oxford vaccine the green light to re-start its US-based trials, the FT is reporting new data that seems promising, even if it's still pretty preliminary.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.